Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Core Insights - Atossa Therapeutics congratulates Dr. Tessa Cigler and her team for receiving a $2.3 million grant from the CDC to improve care for young breast cancer patients in New York City [1][2][3] Group 1: Grant and Initiative Details - The CDC grant will fund initiatives aimed at enhancing equitable access to care, quality of life, and survival outcomes for young breast cancer patients [1] - Dr. Cigler will collaborate with Dr. Vered Stearns and a multidisciplinary team to address the unique needs of young breast cancer patients from diverse backgrounds [2] - The program will focus on care coordination, culturally relevant resources, and targeted interventions for the physical, emotional, and mental well-being of patients and caregivers [2] Group 2: Company Support and Vision - Atossa Therapeutics expresses pride in Dr. Cigler's dedication to advancing breast cancer care and addressing health disparities [3] - The company supports innovative and inclusive approaches to breast cancer treatment and survivorship [3] - Atossa looks forward to the positive impact of the initiative on young breast cancer patients and their families [3] Group 3: Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for significant unmet medical needs in oncology, particularly breast cancer [4]